professor Sarah Wordsworth
BSc MSc PhD
Professor of Health Economics
I joined the Health Economics Research Centre in January 2003 and developed a research programme on the economics of genetic and genomic technologies. Of particular interest are the economics of translating high-throughput sequencing technologies such as whole genome sequencing in rare diseases and cancer into health care systems.
My other research interests include antimicrobial resistance (AMR) where I explore the contribution that health economics can bring to this important health area and identify barriers to implementing interventions for reducing AMR. I also address methodological challenges in trial based economic evaluations in the areas of surgery for obesity, lung cancer surgery, cardiovascular disease and eye disease.
I undertake policy work and lead the Health Economics Genomics England Clinical Interpretation Partnership (GeCIP). for the UK’s 100,000 Genomes Project. This is the largest sequencing initiative in the world, and sequenced 100,000 entire genomes from around 70,000 National Health Service patients with rare diseases and cancer.
As a Senior Fellow at St. Anne’s College I am a member of the college Governing Body, graduate advisor for DPhil and MSc students and part of the Centre for Personalised Medicine (St. Anne’s and Wellcome Trust Centre for Human Genetics).
I teach a variety of undergraduate and graduate students, I am also Co-Director of the MSc in Precision Cancer Medicine (University of Oxford) and supervise DPhil students.
I worked in the Health Economics Research Unit at the University of Aberdeen from 1995-2002, after completing my MSc in Health Economics in 1995 at the University of York.
Adalimumab vs placebo as add-on to Standard Therapy for autoimmune Uveitis: Tolerability, Effectiveness and cost-effectiveness-a protocol for a randomised controlled trial (ASTUTE trial).
Hazell M. et al, (2024), BMJ Open, 14
Population screening requires robust evidence-genomics is no exception.
Turnbull C. et al, (2023), Lancet
Cost-effectiveness of genetic-based screening strategies for maturity-onset diabetes of the young.
Kovács G. et al, (2023), Per Med
Lessons learned from the application of the HEcoPerMed guidance to three modeling case studies.
Nagy B. et al, (2023), Per Med
Cost-effectiveness of extended DPYD testing before fluoropyrimidine chemotherapy in metastatic breast cancer in the UK.
Koleva-Kolarova R. et al, (2023), Per Med